Volume 5.12 | Apr 4

Prostate Cell News 5.12 April 4, 2014
Prostate Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter
 
TOP STORY
The NLR-Related Protein NWD1 Is Associated with Prostate Cancer and Modulates Androgen Receptor Signaling
Researchers identified the cytosolic NLR-related protein NWD1 as a novel modulator of androgen receptor signaling. Experiments with cultured cells showed that NWD1 expression is up-regulated by the sex-determining region Y family proteins. [Oncotarget] Abstract
[Watch the Video] Detect Cancer Stem Cells with ALDEFLUOR™.
 
PUBLICATIONS (Ranked by impact factor of the journal)
LABORATORY RESEARCH

Natural Compound Alternol Induces Oxidative Stress-Dependent Apoptotic Cell Death Preferentially in Prostate Cancer Cells
Researchers evaluated the anti-cancer effect of a recently isolated natural compound Alternol in multiple prostate cancer cell lines with the properties of advanced prostate cancers in comparison to prostate-derived non-malignant cells. [Mol Cancer Ther] Abstract | Full Article

Prostate Tumor OVerexpressed-1 (PTOV1) Down-Regulates HES1 and HEY1 Notch Targets Genes and Promotes Prostate Cancer Progression
Knockdown of PTOV1 in prostate epithelial cells and HaCaT skin keratinocytes caused the upregulation, and overexpression of PTOV1 the downregulation of the Notch target genes HEY1 and HES1, suggesting that PTOV1 counteracts Notch signaling. [Mol Cancer] Abstract | Full Article

Methylation of the PMEPA1 Gene, a Negative Regulator of the Androgen Receptor in Prostate Cancer
Researchers focused on epigenetic mechanisms of reduced prostate transmembrane protein androgen induced (PMEPA1) expression in the cancer of the prostate (CaP). Cell culture-based studies demonstrated that decitabine restores PMEPA1 expression in androgen receptor-positive CaP cell lines. [Epigenetics] Full Article

6-Shogaol from Dried Ginger Inhibits Growth of Prostate Cancer Cells Both In Vitro and In Vivo through Inhibition of STAT3 and NF-?B Signaling
The effect of 6-Shogaol (6-SHO) on the growth of prostate cancer (PCa) cells was investigated. 6-SHO effectively reduced survival and induced apoptosis of cultured human and mouse PCa cells. [Cancer Prev Res] Abstract

Inactivation of ATP Citrate Lyase by Cucurbitacin B, a Bioactive Compound from Cucumber, Inhibits Prostate Cancer Growth
Scientists reported that cucurbitacin B (CuB) significantly and specifically inhibited prostate cancer cell growth with low IC50, accompanied by marked apoptosis, whereas normal human prostate epithelial cells were CuB-insensitive. [Cancer Lett] Abstract

A General Synthetic Strategy and the Anti-Proliferation Properties on Prostate Cancer Cell Lines for Natural Phenylethanoid Glycosides
A preliminary study of the anti-proliferation properties of the PhG compounds echinacoside, acteoside, calceolarioside-A and calceolarioside-B was performed; acteoside exhibited the best inhibition on the prostatic cancer cell proliferation. [Org Biomol Chem] Abstract

Linc00963: A Novel, Long Non-Coding RNA Involved in the Transition of Prostate Cancer from Androgen-Dependence to Androgen-Independence
Researchers investigated the long non-coding RNAs expression profiles of the indolent, androgen-dependent LNCaP cell line to the aggressive metastatic, androgen-independent C4-2 cell line using microarray technology. [Int J Oncol] Abstract

Mitochondrial Structure Alteration in Human Prostate Cancer Cells upon Initial Interacting with a Chemopreventive Agent Phenethyl Isothiocyanate
Human prostate cancer LNCaP cells were exposed to phenethyl isothiocyanate and the effects on cellular fine structure examined by transmission electron microscopic studies. [Cancer Cell Int] Abstract | Full Article

CLINICAL RESEARCH

External Validation of a Prognostic Model Predicting Overall Survival in Metastatic Castrate-Resistant Prostate Cancer Patients Treated with Abiraterone
A prognostic model was derived from the population of the COU-AA-301 Phase III trial for metastatic castrate-resistant prostate cancer patients treated with abiraterone after docetaxel, and it stratifies patients into three risk groups based on clinical parameters. [Eur Urol] Abstract

A Randomized Phase II Efficacy and Safety Study of Vandetanib (ZD6474) in Combination with Bicalutamide Versus Bicalutamide Alone in Patients with Chemotherapy Naïve Castration-Resistant Prostate Cancer
Scientists investigated the efficacy and safety of combining vandetanib, an orally available multi-targeted tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2 and epidermal growth factor receptor, with bicalutamide in patients with metastatic castration-resistant prostate cancer. [Invest New Drugs] Abstract

ProstaCult™: Serum-Free, BPE-Free Medium for Mouse Prostate Colony Assays - FREE Sample Request
 
REVIEWS
Overdetection in Screening for Prostate Cancer
The authors describe mechanisms behind and extent of overdetection in prostate cancer screening as well as possible ways to avoid unnecessary overdiagnosis. [Curr Opin Urol] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.
 
INDUSTRY NEWS
Astellas Announces European Regulatory Submission for XTANDI® (Enzalutamide) Capsules for Chemotherapy-Naive Metastatic Prostate Cancer
Astellas Pharma Inc. announced the submission of a variation to amend the Marketing Authorization Application for XTANDI™ capsules for the treatment of adult men with metastatic castration-resistant prostate cancer who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and in whom chemotherapy is not yet clinically indicated. [Astellas Pharma Inc.] Press Release

Bayer Initiates Phase III Trial of Radium-223 Dichloride in Combination with Abiraterone Acetate for Patients with Metastatic Castration-Resistant Prostate Cancer
Bayer HealthCare announced that the company has begun to enroll patients in a new Phase III trial with radium-223 dichloride. The study evaluates radium-223 in combination with abiraterone acetate and prednisone/prednisolone for the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients with bone predominant metastatic castration-resistant prostate cancer. [Bayer AG] Press Release

From our sponsor: Learn about assays for cord blood. Download the free technical bulletin.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW Tissue Engineering & Regenerative Medicine International Society (TERMIS) – Europe 2014
June 10-13, 2014
Genoa, Italy

Visit our events page to see a complete list of events in the prostate cell community.
 
JOB OPPORTUNITIES
NEW MSc & PhD Positions – Cell Biology, Neurobiology, Neuroimmunology, Cancer Biology, Computational Biology (Hanyang University)

NEW Postdoctoral Research Associate – Extracellular Microenvironment in Cancer (Institute of Translational Medicine, University of Liverpool)

NEW Postdoctoral Fellow – Biological Markers and Novel Targets for Aggressive Breast and Prostate Cancer (University of Bergen)

NEW Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Postdoctoral Position – Stem Cells and Cancer (Brigham & Women’s Hospital – Harvard Medical School)

Postdoctoral Fellows – Small-Molecule Drugs in the Treatment of Prostate Cancer Bone Metastasis (Georgia Regents University Cancer Center)

Studentship – Targeting WW Domain Function in Ubiquitin Ligases Overexpressed in Prostate Cancer (University of East Anglia)

Director of GMP/GLP Quality Operations (University of Pennsylvania, Perelman School of Medicine)

Postdoctoral Position – Molecular Mechanisms and Translational Investigations of Advanced Prostate Cancer (Cleveland Clinic)

Postdoctoral Fellow – Prostate Cancer (Mayo Clinic- Rochester)

Postgraduate Position – Chemokine Receptor Induced Cell Migration (University of East Anglia)

Research Technologist – Pluripotent Stem Cells (STEMCELL Technologies Inc.)

Research Technologist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – PSC Biology and Bioengineering (STEMCELL Technologies Inc.)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Submit your feedback here.
Learn more about Prostate Cell News: Archives | Events | Contact Us